New drug tested for rare brain disease PSP

NCT ID NCT04993768

Completed Disease control Sponsor: Transposon Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a drug called TPN-101 in 42 people with progressive supranuclear palsy (PSP), a rare brain disease that affects movement and thinking. The main goal was to see if the drug is safe and tolerable over 48 weeks. Researchers also looked at how the drug moves in the body and its effects on brain health.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROGRESSIVE SUPRANUCLEAR PALSY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

progressive supranuclear palsy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROGRESSIVE SUPRANUCLEAR PALSY

Contacts and locations

Locations

Cleveland Clinic Lou Ruvo Center for Brain Health

Las Vegas, Nevada, 89106, United States
Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States
Irving Center for Clinical and Translational Research

New York, New York, 10032, United States
Johns Hopkins University School of Medicine

Baltimore, Maryland, 21287, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Mayo Clinic

Rochester, Minnesota, 55905, United States
Parkinson's Disease and Movement Disorders Center of Boca Raton

Boca Raton, Florida, 33486, United States
Quest Research Institute

Farmington Hills, Michigan, 48334, United States
Rocky Mountain Movement Disorders Center

Englewood, Colorado, 80113, United States
St. Joseph's Hospital and Medical Center, Barrow Neurological Institute

Phoenix, Arizona, 85013, United States
UC San Diego Altman Clinical And Translational Research Institute

La Jolla, California, 92037, United States
UCSF Neurosciences Clinical Research Unit (NCRU)

San Francisco, California, 94158, United States
UFHealth Fixel Institute for Neurological Diseases

Gainesville, Florida, 32608, United States
University of Texas Southwestern Medical Center

Dallas, Texas, 75390, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.